Global trends in molecular epidemiology of HIV-1 during 2000-2007

• Autores: Hemelaar, Joris; Gouwsb, Eleanor; Ghysb, Peter D.; Osmanov, Saladin; WHO-UNAIDS Network for HIV Isolation and Characterisation; Salomon, Horacio Eduardo
• Año de publicación: 2011
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: circulating recombinant form; HIV; molecular epidemiology; recombinant; subtype; vaccine
• Institución: Consejo Nacional de Investigaciones Científicas y Técnicas

Objective To estimate the global and regional distribution of HIV-1 subtypes and recombinants between 2000 and 2007. Design Country-specific HIV-1 molecular epidemiology data were combined with estimates of the number of HIV-infected people in each country. Method Cross-sectional HIV-1 subtyping data were collected from 65913 samples in 109 countries between 2000 and 2007. The distribution of HIV-1 subtypes in individual countries was weighted according to the number of HIV-infected people in each country to generate estimates of regional and global HIV-1 subtype distribution for the periods 2000–2003 and 2004–2007. Results Analysis of the global distribution of HIV-1 subtypes and recombinants in the two time periods indicated a broadly stable distribution of HIV-1 subtypes worldwide with a notable increase in the proportion of circulating recombinant forms (CRFs), a decrease in unique recombinant forms (URFs), and an overall increase in recombinants. In 2004–2007, subtype C accounted for nearly half (48%) of all global infections, followed by subtypes A (12%) and B (11%), CRF02_AG (8%), CRF01_AE (5%), subtype G (5%) and D(2%). Subtypes F, H, J and K together cause fewer than 1% of infections worldwide. Other CRFs and URFs are each responsible for 4% of global infections, bringing the combined total of worldwide CRFs to 16% and all recombinants (CRFs plus URFs) to 20%. Conclusions The global and regional distributions of individual subtypes and recombinants are broadly stable, although CRFs may play an increasing role in the HIV pandemic. The global diversity of HIV-1 poses a formidable challenge to HIV vaccine development.
Fil: Hemelaar, Joris. University of Oxford; Reino Unido
Fil: Gouwsb, Eleanor. UNAIDS; Suiza
Fil: Ghysb, Peter D.. UNAIDS; Suiza
Fil: Osmanov, Saladin. WHO-UNAIDS HIV Vaccine Initiative; Suiza
Fil: WHO-UNAIDS Network for HIV Isolation and Characterisation.
Fil: Salomon, Horacio Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina